BWI-CTU Researchers Elected to ACTG Network Committees

Date: 11/30/2016

November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:

  • Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
     
  • David Hardy, Whitman-Walker Clincial Trials Site (Washington)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore)
    Non-voting Member, Antiretroviral Therapy Strategies Subcommittee.  
        
  • Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India)
    Investigator, Tuberculosis Transformative Science Group.  
       
  • Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, Tuberculosis Transformative Science Group.  
        
  • Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore)
    Chair, Site Management & Clinical Care Committee

Clinical Trials

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More